Vertex Pharma (VRTX): Recent Weakness Skews Risk/Reward To Favorable - Jefferies

October 18, 2016 9:23 AM EDT
Get Alerts VRTX Hot Sheet
Price: $76.56 +0.95%

Rating Summary:
    27 Buy, 14 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 30 | Down: 48 | New: 20
Trade VRTX Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Jefferies analyst, Brian Abrahams, reiterated his Buy rating on shares of Vertex (NASDAQ: VRTX) on the belief that the recent Orkambi launch slowdown and concerns over a no next-gen corrector news are overdone.

The analyst believes that the share price does not fully reflect 1) the potential for cash flow expansion through 3x-combos which should ultimately work, 2) a leadership position and barrier to entry for future competitors, and 3) leverage even if there are stumbles.

The analyst perceives the upside/downside scenarios as favorably skewed at (~50%/13%), creating a highly attractive entry point.

price target of $105.00

For an analyst ratings summary and ratings history on Vertex click here. For more ratings news on Vertex click here

Shares of Vertex closed at $80.50 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Jefferies & Co

Add Your Comment